DE602009001212D1 - Galanthamin-Derivate, Verfahren zu deren Herstellung und Verwendung - Google Patents

Galanthamin-Derivate, Verfahren zu deren Herstellung und Verwendung

Info

Publication number
DE602009001212D1
DE602009001212D1 DE602009001212T DE602009001212T DE602009001212D1 DE 602009001212 D1 DE602009001212 D1 DE 602009001212D1 DE 602009001212 T DE602009001212 T DE 602009001212T DE 602009001212 T DE602009001212 T DE 602009001212T DE 602009001212 D1 DE602009001212 D1 DE 602009001212D1
Authority
DE
Germany
Prior art keywords
galanthamine
galanthamine derivatives
preparation
inhibition
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602009001212T
Other languages
English (en)
Inventor
Lubomir Todorov Vezenkov
Mariya Georgieva Georgieva
Dancho Lubenov Danalev
Chavdar Borisov Ivanov
Anastassia Todorova Bakalova
Krum Krumov Hristov
Vanyo Ivanov Mitev
Frederic Checler
Jean Sevalle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOPHARMA AD
Original Assignee
SOPHARMA AD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOPHARMA AD filed Critical SOPHARMA AD
Publication of DE602009001212D1 publication Critical patent/DE602009001212D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602009001212T 2008-05-23 2009-02-24 Galanthamin-Derivate, Verfahren zu deren Herstellung und Verwendung Active DE602009001212D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG10110141A BG110141A (en) 2008-05-23 2008-05-23 GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE

Publications (1)

Publication Number Publication Date
DE602009001212D1 true DE602009001212D1 (de) 2011-06-16

Family

ID=40671399

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602009001212T Active DE602009001212D1 (de) 2008-05-23 2009-02-24 Galanthamin-Derivate, Verfahren zu deren Herstellung und Verwendung

Country Status (6)

Country Link
EP (1) EP2123328B1 (de)
AT (1) ATE507881T1 (de)
BG (1) BG110141A (de)
DE (1) DE602009001212D1 (de)
PL (1) PL2123328T3 (de)
SI (1) SI2123328T1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247405B2 (en) * 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
JP2013500268A (ja) * 2009-07-23 2013-01-07 シャイア エルエルシー ガランタミンアミノ酸およびペプチドプロドラッグならびにその使用
BG67337B1 (bg) * 2018-05-23 2021-06-15 Софарма Ад Метод за получаване на пречистен галантамин хидробромид

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016751A1 (es) 1996-11-22 2001-08-01 Athena Neurosciences Inc Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
AU5585198A (en) 1996-11-22 1998-06-10 Athena Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and ethods for inhibiting beta-amyloid peptide release and/or its synthesis
CA2368966A1 (en) * 2000-03-31 2001-10-11 Sanochemia Pharmazeutika Aktiengesellschaft New derivatives and analogues of galanthamine
US20040254146A1 (en) * 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2008022365A2 (de) * 2006-08-24 2008-02-28 Sanochemia Ltd. Mittel zum beeinflussen der wirkungen von organophosphorverbindungen und verwendung von galanthamin, dessen derivaten und analoga zum herstellen solcher mittel

Also Published As

Publication number Publication date
SI2123328T1 (sl) 2011-08-31
ATE507881T1 (de) 2011-05-15
PL2123328T3 (pl) 2011-10-31
EP2123328A1 (de) 2009-11-25
EP2123328B1 (de) 2011-05-04
BG110141A (en) 2009-12-31

Similar Documents

Publication Publication Date Title
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
EA201690787A1 (ru) Соединения и их применение в качестве ингибиторов фермента расщепления бета-сайта app (bace)
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
EA201190020A1 (ru) Производные изоиндола в качестве ингибиторов васе и их применение
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
DE602005015697D1 (de) Te zur behandlung von alzheimer-krankheit
ATE457985T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
DE602009001212D1 (de) Galanthamin-Derivate, Verfahren zu deren Herstellung und Verwendung
ATE432930T1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE407126T1 (de) Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
ATE540042T1 (de) Annelierte 4-(indazolyl)-1,4- dihydropyridinderivate als c-met-mediatoren
TW200510351A (en) Oxazole compounds for the treatment of neurodegenerative disorders
ATE471322T1 (de) Substituierte pyrazinonderivate zur verwendung als arzneimittel
ATE473219T1 (de) Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
MY145068A (en) Imidazole compounds for the treatment of neurodegenerative disorders